Articles of the Month
Videos
Articles
Dynamic Regulation of Collagens, Proteases, Their Inhibitors, and Cell Death in Experimental Asthma in Mice
M. Tynecka, A. Tarasik, B. Hanczaruk, et al., et al. Allergy. First published:28 October 2025
Bidirectional Associations Between Seborrheic Dermatitis and Epithelial Barrier Diseases: A Retrospective Cohort Study
S. Meng, R. Berna, J. Takeshita, et al. Allergy. First published: October 2025
The CXCL12-CXCR4 Axis Mediates Lymphocyte Immune Overactivation in IgG4-Related Chronic Rhinosinusitis
J. Ding, L. Cui, C. Wang, et al. Allergy. First published: 27 October 2025
Role of Inflammasome in IgE-Mediated Anaphylaxis
S. Fernandez-Bravo and R. Fernandez-Santamaria. Allergy. First published:25 October 2025
Increased Cardiovascular Risk in Chronic Spontaneous Urticaria: A Large Real-World Cohort Study
P. Curman, D. Thaçi, and R. J. Ludwig. Allergy. First published:25 October 2025
Cellular Stress, Inflammation and Barrier Damage in Gut Epithelial Cells Caused by Aspartame
Y. Pat, D. Yazici, C. Zeyneloglu, et al. Allergy. First published: 24 October 2025
Protective Role for Itaconate During Inhaled Allergen Challenge
G. J. Albers, P. P. Ogger, C. Michalaki et al. Allergy. First published: 24 October 2025
On the Kinetics of Human Skin Mast Cell Depletion and Repopulation Following KIT Inhibition
D. Alvarado, D. M. Maurer, P. Golden, et al. Allergy. First published: 24 October 2025
Wildfires and Atopic Diseases: A Review
A. Ha, J. R. Balmes, and M. L. Wei. Allergy. First published: 23 October 2025
Club Cells in Nasal Epithelial Repair: Insights From an IL-13-Induced Inflammatory Model
Z.-Q. Huang, J. Liu, J. Ye, et al. Allergy. First published: 22 October 2025
The Therapeutic Potential of Farm Dust Extracts in a Mouse Model of Eosinophilic Inflammation
R. Ü. Korkmaz, J. Omony, X. Tan, et al. Allergy. First published: 22 October 2025
Unifying Global Drug Allergy: Clarifying Concepts and Defining Low-Risk Penicillin Allergy
Li, P.H., Sabato, V., Khan, D.A., et al. Allergy. First published: 22 October 2025
Not All Rhinitis Follows the Atopic March: Early-Life Risk Factors and Implications of Infectious Disease Across Three Phenotypes in JECS Cohort
D. Harama, M. Saito-Abe, K. Pak, et al.,Allergy. First published: 21 October 2025
Human KIT Antibody Briquilimab Diminishes Anaphylactic Responses in Mice Expressing Chimeric Human-Mouse KIT
H.-S. Kwon, S. E. Lee, A. Sharma, et al. Allergy. First published: 21 October 2025
High Serum TSLP Is Characteristic of Late-Onset, Long-Duration, Eosinophilic Asthma
M. Suzukawa, K. Ohta, H. Tashimo, et al. Allergy. First published: 21 October 2025
An Anti-IL-13 Vaccine Reduces Atopic Dermatitis in Humanized Mice and Induces Neutralizing Antibodies in Nonhuman Primates
A. Mougel, K. Lemdani, N. Serhan, et al. Allergy. First published: 21 October 2025
Peanut Component-Specific IgE and IgG4 Are Modulated by Sublingual Immunotherapy and Are Associated With Remission in 1–4-Year-Old Children
N. Singh, J. Kesselring, J. Humphrey, et al. Allergy. First published: 21 October 2025
Safety of Drug Provocation Tests in Adults With and Without Clonal Mast Cell Disorders
F. Nalin, B. Olivieri, F. Olivieri, et al. Allergy. First published: 21 October 2025
Thaumatin-Like Proteins in Molecular Allergy Diagnostics: Uncommon Co-Sensitized, and Clinically Inconspicuous? Insights From an Italian Cohort
E. Scala, D. Abeni, M. Giani, et al. Allergy. First published: 21 October 2025
Prolonged IL-33 Exposure Switches the Secreted Mast Cell Cytokine Profile From Pro-Inflammatory to Pro-Tolerant
A. R. Teufelberger, C. Költgen, M. Babina, and P. Wolf. Allergy. First published:21 October 2025
Heavy Metals as Key Environmental Aggravators in Atopic Dermatitis in Companion Dogs: A One Health Perspective
J. Han, H.-W. Cha, Y. Eom, et al. Allergy. First published: 20 October 2025
Intrinsic Alterations of the Inflammatory Pathways in Primary Canine Atopic Keratinocytes
D. Santoro, L. Archer, G. Scotti, K. Ahrens, and A. Riva. Allergy. First published: 17 October 2025
Immune Training of the Interleukin 6 Gene in Airway Epithelial Cells is Central to Asthma Exacerbations
L. P. Lunding, M. Weckmann, U. M. Zissler et al. Allergy. First published: 16 October 2025
Ocular Microbiome in Dupilumab-Induced Ocular Surface Disease
A. Leonardi, R. Frizzo, F. Cavarzeran, et al. Allergy. First published: 16 October 2025
Asthma Remission in Adults: Role of Age at Asthma Onset, Smoking, Obesity, and Allergic Rhinitis
R. Abohalaka, S. Ercan, L. Lehtimäki, et al. Allergy. First published: 15 October 2025
Single Cell Analysis Reveals Dynamic Changes of Distinct Cell Populations in Human Nickel Allergy
M. Schmidt, A. Knorz, K. Mederet al. Allergy. First published: 15 October 2025
National Audit of Long-Term Real-World Outcomes of Berotralstat Use in UK Patients With Hereditary Angioedema
H. Elbashir, A. Dorr, M. Ahuja et al. Allergy. First published: 14 October 2025
Antibiotics for Acute Wheezing and Asthma Exacerbations: An EAACI Position Paper and Systematic Review
A.-L. Redel, W. Feleszko, M. Atanaskovic-Markovic, et al. Allergy. First published: 13 October 2025
Efficacy of Dupilumab in Asthma: Focus on Early, Progressive, and Long-Lasting Effects on Small Airways
M. Martini, L. Antonicelli, M. S. Garritani, et al. Allergy. First published:13 October 2025
Nasopharyngeal Microbiome-Epigenome-Wide Association Analysis in Infants With Severe Bronchiolitis
R. Shibata, Y. Li, A. Yaskolka Meir, et al. Allergy. First published: 13 October 2025
The Nasal Microbiome and Associations With Environmental Exposures and Respiratory Health
J. Perez-Garcia, A. K. Bozack, S. L. Rifas-Shiman, et al. Allergy. First published: 11 October 2025
Basophils in Skin-Mediated Sensitization Drive Subsequent Lung Inflammation in Airway-Challenged Mice
E. D. Choi, D. Voehringer, and D. Radtke. Allergy. First published: 11 October 2025
The Sting Challenge Test: An EAACI Position Paper on Hymenoptera Venom Allergy
A. V. Castro, C. Breynaert, T. Alfaya, et al. Allergy. First published: 11 October 2025
Genistein Reduced Eosinophilic Inflammation and Remodeling by Downregulating PAI-1 and TSLP
J. Y. Han, J.-Y. Lee, C.-G. Jung,et al. Allergy. First published: 11 October 2025
Forever Chemicals: An Exploratory, Population-Based Analysis of Per- and Polyfluoroalkyl Substances Exposure and Effects on Sinonasal Health
Chiang, S., Jung, Y.S., Thorley, W., et al. Allergy. First published:10 October 2025
SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma: A Randomised Phase III Trial
G. Roberts, J. Just, H. Nolte, et al. Allergy. First published:09 October 2025
Genome-Wide Blood DNA Methylation Profiling in Birch Pollen Allergic Patients Undergoing Allergen-Specific Immunotherapy
A. Lahnsteiner, V. Ellmer, M. Hao, et al. Allergy. First published: 09 October 2025
Dupilumab in Children Under 6 Years With Moderate-to-Severe Atopic Dermatitis: A 16-Week Real-World Prospective Study on Efficacy, Safety, and Local-Systemic Immune Responses
Y. Zhang, J. Pi, L. Wang, et al.Allergy. First published: 07 Ocotober 2025
Asthma in Pregnancy
E. Denton, M. E. Jensen, B. K. Brew, et al. Allergy. First published:06 October 2025
Secretion of Peanut Protein With IgE Crosslinking Capacity in Human Milk
A. D. Burris, N. Diaz, J. B. Meddings, et al. Allergy. First published:01 October 2025
Long-Term, Real-World Effectiveness of Allergen Immunotherapy in Children and Adolescents With Allergic Rhinitis and Asthma
C. Woehlk, T. Stranzl, M. Contoli, et al. Allergy. First published: 01 October 2025
Citations: 342
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, Aquilina, S, Asero, R, Baker, D, et al. Allergy. 2022; 77: 734– 766
Citations: 147
EAACI guidelines: Anaphylaxis (2021 update)
Muraro A, Worm M, Alviani C, et al. Allergy. 2022; 77: 357–377
Citations: 118
The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update
Maurer M, Magerl M, Betschel S, et al. Allergy. 2022; 77: 1961–1990
Citations: 118
The role of peripheral blood eosinophil counts in COVID-19 patients
Xie, G, Ding, F, Han, L, Yin, D, Lu, H, Zhang, M. Allergy. 2021; 76: 471– 482
Citations: 114
Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease
Celebi Sozener Z, Ozdel Ozturk B, Cerci P, et al. Allergy. 2022; 77: 1418–1449
Citations: 105
Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice
Santos, A.F., Alpan, O. and Hoffmann, H.-J. Allergy. 2021; 76: 2420-2432
Citations: 92
Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation
Klimek, L., Novak, N., Cabanillas, B., et al. Allergy. 2021; 76: 3307-3313
Citations: 90
EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines
Sokolowska, M., Eiwegger, T., Ollert, M., Torres, M.J., Barber, D., Del Giacco, S., et al. Allergy. 2021; 76: 1629-1639
Citations: 88/h5>
The role of allergen-specific IgE, IgG and IgA in allergic disease
Shamji MH, Valenta R, Jardetzky T, et al. Allergy. 2021; 76: 3627–3641
Citations: 82
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper
Pfaar, O, Klimek, L, Jutel, M, Akdis, C, A, Bousquet, J, Breiteneder, H, et al. Allergy. 2021; 76: 648– 676
Citations: 81
Advances and highlights in allergic rhinitis
Zhang Y, Lan F, Zhang L. Allergy. 2021; 76: 3383–3389
Citations: 79
Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?
Cabanillas, B., Akdis, C.A. and Novak, N. Allergy. 2021; 76: 1617-1618
Citations: 76
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines
Agache, I., Song, Y., Alonso-Coello, P., Vogel, Y., Rocha, C., Solà, I., et al. Allergy. 2021; 76: 2337-2353
Citations: 74
Interleukin-31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997
Citations: 73
Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches
Kato A, Peters AT, Stevens WW, Schleimer RP, Tan BK, Kern RC. Allergy. 2022; 77: 812–826
Citations: 70
Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives
Sampath, V., Rabinowitz, G., Shah, M., et al. Allergy. 2021; 76: 1640-1660
Citations: 69
Advances and highlights in biomarkers of allergic diseases
Ogulur I, Pat Y, Ardicli O, et al. Allergy. 2021; 76: 3659–3686
Citations: 69
Regulatory B cells, A to Z
Jansen, K., Cevhertas, L., Ma, S., Satitsuksanoa, P., Akdis, M. and van de Veen, W.
Citations: 62
Advances and highlights in asthma in 2021
Agache I, Eguiluz-Gracia I, Cojanu C, et al. Allergy. 2021; 76: 3390–3407
Citations: 62
Predictors of treatment response in chronic spontaneous urticaria
Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981
Citations: 61
The ingenious mast cell: Contemporary insights into mast cell behavior and function
Dahlin, J.S., Maurer, M., Metcalfe, D.D., Pejler, G., Sagi-Eisenberg, R. and Nilsson, G. Allergy. 2022; 2022; 77: 83-99
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, et al. Allergy. 2022; 77: 734– 766
The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A., H., Baker, D., Ballmer-Weber, B. et al. Allergy. 2018; 73: 1393- 1414
Risk factors for severe and critically ill COVID-19 patients: A review
Gao, Y-D, Ding, M, Dong, X, et al. Allergy. 2021; 76: 428– 455
Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives
Sampath, V., Rabinowitz, G., Shah, M., Jain, S., Diamant, Z., Jesenak, M. et al. Allergy. 2021; 76: 1640-1660
Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19
Azkur, A.,K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M.,C. et al. Allergy. 2020; 75: 1564– 1581
EAACI guidelines: Anaphylaxis (2021 update)
Muraro, A, Worm, M, Alviani, C, et al. Allergy. 2022; 77: 357– 377
Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
Bousquet, J., Khaltaev, N., Cruz, A.A., Denburg, J., Fokkens, W.J., Togias, A. et al. Allergy. 2008; 63: 8-160
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China
Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yan, Y.-Q., Akdis, C., A. and Gao, Y.-D. Allergy. 2020; 75: 1730– 1741
Advances and recent developments in asthma in 2020
Cevhertas, L, Ogulur, I, Maurer, DJ, et al. Allergy. 2020; 75: 3124– 3146
The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update
Maurer, M., Magerl, M., Betschel, S., et al. Allergy. First published: 10 January 2022
A compendium answering 150 questions on COVID-19 and SARS-CoV-2
Riggioni, C., Comberiati, P., Giovannini, M., Agache, I., Akdis, M., Alves-Correia, M. et al. Allergy. 2020; 75: 2503– 2541
Special Issue: Perspectives in Allergen Immunotherapy: 2019 and Beyond
Volume 74 | Issue S108
Management of anaphylaxis due to COVID-19 vaccines in the elderly
Bousquet, J., Agache, I., Blain, H., et al. Allergy. 2021; 76: 2952-2964
Predictors of treatment response in chronic spontaneous urticaria
Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981
Interleukin-31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997
Markers for the involvement of endothelial cells and the coagulation system in chronic urticaria: A systematic review
Mostmans, Y., De Smedt, K., Richert, B., et al. Allergy. 2021; 76: 2998-3016
Eczema herpeticum in atopic dermatitis
Traidl, S., Roesner, L., Zeitvogel, J. and Werfel, T. Allergy. 2021; 76: 3017-3027
CytoBas: Precision component-resolved diagnostics for allergy using flow cytometric staining of basophils with recombinant allergen tetramers
McKenzie, C.I., Varese, N., Aui, P.M., et al. Allergy. 2021; 76: 3028-3040
Heterogeneity of pollen food allergy syndrome in seven Southern European countries: The @IT.2020 multicenter study
Lipp, T, Acar Şahin, A, Aggelidis, X, et al. Allergy. 2021; 76: 3041– 3052
Direct assessment of individual skin barrier components by electrical impedance spectroscopy
Mannweiler, R., Bergmann, S., Vidal-y-Sy, S., Brandner, J.M. and Günzel, D. Allergy. 2021; 76: 3094-3106
Prenatal paraben exposure and atopic dermatitis-related outcomes among children
Thürmann, L, Herberth, G, Seiwert, B, et al. Allergy. 2021; 76: 3122– 3132
Free human DNA attenuates the activity of antimicrobial peptides in atopic dermatitis
Kopfnagel, V, Dreyer, S, Zeitvogel, J, et al. Allergy. 2021; 76: 3145– 3154
Nanoarchitectures for efficient IgE cross-linking on effector cells to study amoxicillin allergy
Tesfaye, A., Rodríguez-Nogales, A., Benedé, S., et al. Allergy. 2021; 76: 3183-3193
Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine
Darrigade, A.-S., Théophile, H., Sanchez-Pena, P., et al. Allergy. 2021; 76: 3194-3196
Transgenic mice overexpressing the PGE2 receptor EP2 on mast cells exhibit a protective phenotype in a model of allergic asthma
Urbano, A., Plaza, J., Turon, S., et al. Allergy. 2021; 76: 3196-3199
Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma
Lommatzsch, M., Klein, M., Stoll, P. and Virchow, J.C. Allergy. 2021; 76: 3199-3202
Identification of Ulocladium chartarum as an important indoor allergen source
Pfeiffer, S., Sandler, P., Raith, M., et al. Allergy. 2021; 76: 3202-3206
Effects of allergen immunotherapy in the MASK-air study: a proof-of-concept analysis
Pfaar, O., Sousa-Pinto, B., Devillier, P., et al. Allergy. 2021; 76: 3212-3214
Predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance
Remington, B.C., Koppelman, S.J., Green, T.D., et al. Allergy. 2021; 76: 3223-3226
Legends of allergy and immunology: Sergio Bonini
Maltese, G. and Rasi, G. Allergy. 2021; 76: 3227-3229
Medical algorithm: Peri-operative management of mastocytosis patients
Bocca-Tjeertes, I.F.A., van de Ven, A.A.J.M., Koppelman, G.H., et al. Allergy. 2021; 76: 3233-3235
Open Access Agreements with Wiley
Check here if your research institution has an agreement with Wiley to make your Original Articles and Review Articles free to read, download and share by everyone: Institutional Payments | Wiley
Junior Members Corner
Dear Juniors,
During the biannual congress of our sister society, the European Rhinologic Society, held in Budapest, Hungary, our EAACI JMA representatives Fabio Ryser and Jitesh Chauhan had the chance to attend sessions on the latest advances in rhinology, immunology, and surgical innovation, with special focus on artificial intelligence and radiomics. A highlight was the ERS Junior Round Table, showcasing case-based approaches to enhance junior training.
Our JMA members also actively participated in the Allergy School in Florence, Italy (4–6 September 2025), a highly successful event. Alongside traditional scientific sessions, practical workshops covered topics ranging from immunological pathways to clinical management and emerging therapies in Type-2 diseases.
Later in September, the Clemens von Pirquet Foundation, in collaboration with EAACI JMA, organised a 2-day meeting in Zurich (12–13 September 2025) titled “From inborn errors of immunity to highly prevalent immune-mediated diseases: understanding crucial pathogenetic mechanisms to develop a Precision Medicine approach in Allergology and Clinical Immunology.” This intimate meeting brought juniors and seniors together to exchange knowledge, foster critical discussion, and highlight the latest advances in the field in a constructive and inspiring atmosphere.
We warmly thank our Junior members for their strong involvement in EAACI and sister society activities.
Best regards,
The Junior Member Assembly
EAACI Patients Organisation Committee Corner
The POC Reunion in the Annual Congress 2023
The POC has been participating in the EAACI Annual Congresses and focused meetings such as FAAM and PAAM since 2011. When Covid-19 pandemic and strict public health measures started in 2020, POC members continued attending the EAACI events virtually. For the first time in a long while, the POC returned to in-person participation in the Annual Congress Hamburg 2023.
Fifteen members of the committee attended the Annual Congress 2023 in-person. The special session ESS1 which was completely organised by the POC took place on the first day of the Congress with great success. Session was designed to discuss the “Benefits of engaging with patients in clinical trials and decision-making” with different stakeholders.
Giulia Gabrielli from European Medicine Agency (EMA) shared the framework for engagement between the Agency and the patients. Dr Kirsten Perrett, Director of Australia National Allergy Centre of Excellence, shared their experience in receiving the federal funding for allergy prevention and management in collaboration with the POC member Allergy & Anaphylaxis Australia. Susanna Palkonen, Director of European Federation of Allergy and Airways Diseases Patients Associations (EFA) presented their long-lasting track record in participation to research projects. POC Member Mikaela Odemyr, President of Asthma and Allergy Association Sweden shared her experience as a patient representative in participating the research design and planning process.
The session chairs were Carla Jones, CEO of Allergy UK, past POC Co-Chair and Ozlem Ceylan, President of Living with Allergy Association, current POC Chair. The session also had a panel discussion where chairs invited the audience to share their experiences and best practises.
Additionally, POC members Sabine Schnadt (DAAB-Germany) presented “Managing the risk of patients with peanut allergy: the value of thresholds of reaction” in the industry session, Patricia Carmelo and Carolina Olivares (Fundacion Creciendo con Alergias Alimenarias-Chile) had two poster presentations; “Food Allergens that trigger anaphylaxis in children in Chile” and “Adrenaline Auto-injector in Chile, National Survey 2020”.
Several POC members attended the Beat Allergy Run & Walk on the 10th of June. The event was organised to contribute on providing much-needed aid as the collected funds were sent to those affected by the earthquakes in Turkey.
The POC believes the conferences and in-person meetings are useful in staying up to date with new developments in medicine, dissemination of knowledge, enabling interaction with opinion leaders, networking, developing consensus, and adoption of newer ideas relevant to the patient community. Going forward, committee members consider hybrid conventions a decent opportunity to increase accessibility and inclusivity. In 2024, POC is planning to attend the Annual Congress in Valencia and FAAM in Athens.
